LAG 3

View All

AACR 2022 - LAG 3 Immunotherapy
AACR 2022: LAG-3, one of the most trending Next-generation Immunotherapy

Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022. The data demonstrated that the tetravalent and unique structure of FS118 played a ...

Find More

LAG 3 - The Future of Cancer Immunotherapy
LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. Cancer immunotherapy (CI) is recently advancing at a rapid pace and can be considered as the “fifth pillar” of cancer treatment, joining the ranks of radiation, cytotoxic chemotherapy, ...

Find More